Patents by Inventor Stephen Chappell

Stephen Chappell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110320422
    Abstract: Systems and methods are provided to deliver business information to users through users' online address books. Data aggregation servers associate individual businesses with one or more unique identifiers. The data aggregation servers collect, store and periodically update business information relating to individual businesses from a variety of sources, such as the businesses themselves and third party sources, such as online publications and message boards. The data aggregation servers store the information in association with the unique identifier. Electronic address book applications hosted on user devices store address book entries for individual businesses in local address book databases. The entries for each business include the unique identifier, and the online address book applications use the unique identifier to retrieve business information relating to individual businesses from the data aggregation servers.
    Type: Application
    Filed: June 28, 2010
    Publication date: December 29, 2011
    Applicant: AT&T MOBILITY II LLC
    Inventors: Jack Denenberg, Ely Shemesh, Stephen Chappell
  • Publication number: 20110318371
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Application
    Filed: June 13, 2011
    Publication date: December 29, 2011
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 8053551
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: November 8, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 7968307
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: June 28, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 7928201
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Grant
    Filed: October 7, 2009
    Date of Patent: April 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20100272742
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Application
    Filed: April 16, 2010
    Publication date: October 28, 2010
    Inventors: Daniel E. AFAR, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 7803916
    Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: September 28, 2010
    Assignee: Agensys Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
  • Publication number: 20100190962
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Application
    Filed: October 7, 2009
    Publication date: July 29, 2010
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20100173297
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.
    Type: Application
    Filed: October 7, 2009
    Publication date: July 8, 2010
    Inventors: DANIEL E. AFAR, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20100036807
    Abstract: Systems and methods sort location dependent information based on selecting multiple groups of information according to location, ordering the groups based on location, and ordering the information within the groups based on at least one or more other criteria. The size(s) of the areas used to select the groups may be predetermined, or dynamically determined (e.g., based on clustering of information along distance to a location of interest).
    Type: Application
    Filed: August 5, 2008
    Publication date: February 11, 2010
    Applicant: YELLOWPAGES.COM LLC
    Inventors: Jay H. LIESKE, JR., Stephen CHAPPELL
  • Patent number: 7642054
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” Serpentine TRansmembrane Antigens of the Prostate). Four particular human STRAPs are described and characterized herein. The human STRAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STRAP family, STRAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STRAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and Intracellular N- and C-termini, suggesting that It folds In a “serpentine” manner Into three extracellular and two intracellular loops.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: January 5, 2010
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20090307018
    Abstract: Systems and methods are provided to facilitate the presentation of listings according to levels of user interest in the listings. For example, statistics generated from tracking user interactions with the listings and/or other parameters can be used to measure or estimate a level of current user interest in a listing. Listings in search results can be presented in an order according to the levels of current user interest in the listings.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 10, 2009
    Applicant: YELLOWPAGES COM, LLC
    Inventors: Stephen Chappell, Jay H. Lieske, JR., Samantha Nebrich
  • Publication number: 20090307318
    Abstract: Systems and methods are provided to specify a location of a planned event via a selection of a listing that has location information. For example, in response to a search request a listing may show a business entity at a geographic location; and the user may select the listing as a way to specify the location of a new event or an existing event. In some embodiments, one event can have multiple listings specifying multiple locations.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 10, 2009
    Applicant: YELLOWPAGES COM, LLC
    Inventors: Stephen Chappell, Jay H. Lieske, JR., Samantha Nebrich
  • Publication number: 20090307268
    Abstract: Systems and methods are provided to specify a location of a planned event via a selection of a listing that has location information. For example, in response to a search request a listing may show a business entity at a geographic location; and the user may select the listing as a way to specify the location of a new event or an existing event. In some embodiments, one event can have multiple listings specifying multiple locations.
    Type: Application
    Filed: June 30, 2008
    Publication date: December 10, 2009
    Applicant: Yellowpages.com LLC
    Inventors: Stephen CHAPPELL, Jay H. LIESKE, JR., Samantha NEBRICH
  • Patent number: 7611904
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (SIX Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: November 3, 2009
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Publication number: 20090098629
    Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.
    Type: Application
    Filed: September 16, 2008
    Publication date: April 16, 2009
    Inventors: Daniel E. AFAR, Rene S. Hubert, Stephen Chappell Mitchell
  • Publication number: 20090093049
    Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.
    Type: Application
    Filed: November 6, 2008
    Publication date: April 9, 2009
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech
  • Patent number: 7485299
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: February 3, 2009
    Assignee: Agensys, Inc.
    Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
  • Patent number: 7468275
    Abstract: Synthetic and isolated translational regulatory elements, including oligonucleotides that have translational enhancing activity, internal ribosome entry site (IRES) activity, or translational inhibitory activity, and multimers of such translational regulatory elements are provided. In addition, compositions that include such translational regulatory elements are provided, as are methods of using the translational regulatory elements.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: December 23, 2008
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Geoffrey Owens, Jason K. Pinkstaff, Leslie Krushel, Wei Zhou
  • Patent number: 7456273
    Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: November 25, 2008
    Assignee: The Scripps Research Institute
    Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech